Latest News for: nektar

Edit

Nektar Therapeutics to Participate in Two Investor Conferences in March (Nektar Therapeutics)

Public Technologies 25 Feb 2026
24, 2026/PRNewswire/ -- Nektar Therapeutics (Nasdaq ... The presentation will be accessible via the webcast link above as well as on the Investor Events section of the Nektar website. https.//ir.nektar.com/events-and-presentations/events.
Edit

Nektar Therapeutics to Participate in Two Investor Conferences in March

Independent Record 25 Feb 2026
24, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq.
Edit

Statement of Changes in Beneficial Ownership (Form 4) (Nektar Therapeutics)

Public Technologies 21 Feb 2026
) FORM 4 ... 0.5 ... 2 ... NEKTAR THERAPEUTICS [NKTR] 5 ... C/O NEKTAR THERAPEUTICS, 455 MISSION BAY BLVD SOUTH 3 ... C/O NEKTAR THERAPEUTICS ... Nektar Therapeutics published this content on February 20, 2026, and is solely responsible for the information contained herein.
Edit

The Interim Report for the 12 months of 2025 (unaudited) (Linda Nektar AS)

Public Technologies 20 Feb 2026
2026-02-20 16.00.00 CET Linda Nektar - Company Announcement The Interim Report for the 12 months of 2025 (unaudited) ... In 2025 AS Linda Nektar (the Company´s) unaudited turnover was EUR 2,754,309 (12 months 2024.
Edit

Notice of Proposed Sale of Securities (Form 144) (Nektar Therapeutics)

Public Technologies 18 Feb 2026
Nektar Therapeutics published this content on February 18, 2026, and is solely ...
Edit

Nektar Therapeutics Announces Research Collaboration with UCSF and Dr. Stephen Hauser for NKTR-0165, a Tumor Necrosis Factor Receptor 2 (TNFR2) Antibody, in Multiple Sclerosis

PR Newswire 17 Feb 2026
17, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq ... Hauser on this important research initiative to explore the role of TNFR2 agonism in several models of MS," said Jonathan Zalevsky, Ph.D., Chief Research and Development Officer of Nektar.
Edit

Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option ...

TDN 14 Feb 2026
13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq.
Edit

Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering (Form 8-K) (Nektar Therapeutics)

Public Technologies 13 Feb 2026
Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering. SAN FRANCISCO, February 11, 2026 /PRNewswire/ - Nektar Therapeutics (Nasdaq ... All of the securities being sold in this offering are being offered by Nektar.
Edit

Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares (Nektar Therapeutics)

Public Technologies 13 Feb 2026
13, 2026/PRNewswire/ -- Nektar Therapeutics (Nasdaq ... The gross proceeds to Nektar from the offering were approximately $460 million, before deducting underwriting discounts and commissions and estimated offering expenses ... About Nektar Therapeutics.
Edit

Nektar Therapeutics Announces Closing of $460 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

PR Newswire 13 Feb 2026
13, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq ... The gross proceeds to Nektar from the offering were approximately $460 million, before deducting underwriting discounts and commissions and estimated offering expenses ... SOURCE Nektar Therapeutics.
Edit

Supplemental Prospectus (Form 424B5) (Nektar Therapeutics)

Public Technologies 13 Feb 2026
Our website address is https.//nektar.com ... Our website is located at https.//nektar.com ... Nektar Therapeutics, 455 Mission Bay Boulevard South, San Francisco, CA 94158, Attention ... Our website is located at https.//nektar.com ... Nektar Therapeutics.
Edit

Nektar Therapeutics Announces Pricing of Upsized $400 Million Public Offering

Rio Grande Sun 12 Feb 2026
11, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq.
Edit

Nektar Therapeutics Announces Proposed Public Offering

Corvallis Gazette-Times 11 Feb 2026
10, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq.
Edit

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Maintenance Period for ...

Missoulian 10 Feb 2026
9, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq.
Edit

Regulation FD Disclosure (Form 8-K) (Nektar Therapeutics)

Public Technologies 10 Feb 2026
On February 10, 2026, Nektar Therapeutics (the "Company") announced it had approximately $229.1 million in cash and investments in marketable securities as of January 31, 2026 ... Nektar ...

Article Search

tools
×
×
×
×